Cargando…

Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness

Psoriasis is not optimally controlled in spite of newly developed treatments, possibly due to the difficulty of objectively quantifying the disease’s severity, considering the limitations of the clinical scores used in clinical practice. A major challenge addresses difficult-to-treat areas, especial...

Descripción completa

Detalles Bibliográficos
Autores principales: Nicolescu, Alin Codrut, Ionescu, Marius-Anton, Constantin, Maria Magdalena, Ancuta, Ioan, Ionescu, Sinziana, Niculet, Elena, Tatu, Alin Laurentiu, Zirpel, Henner, Thaçi, Diamant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785802/
https://www.ncbi.nlm.nih.gov/pubmed/36556415
http://dx.doi.org/10.3390/life12122050
_version_ 1784858137393627136
author Nicolescu, Alin Codrut
Ionescu, Marius-Anton
Constantin, Maria Magdalena
Ancuta, Ioan
Ionescu, Sinziana
Niculet, Elena
Tatu, Alin Laurentiu
Zirpel, Henner
Thaçi, Diamant
author_facet Nicolescu, Alin Codrut
Ionescu, Marius-Anton
Constantin, Maria Magdalena
Ancuta, Ioan
Ionescu, Sinziana
Niculet, Elena
Tatu, Alin Laurentiu
Zirpel, Henner
Thaçi, Diamant
author_sort Nicolescu, Alin Codrut
collection PubMed
description Psoriasis is not optimally controlled in spite of newly developed treatments, possibly due to the difficulty of objectively quantifying the disease’s severity, considering the limitations of the clinical scores used in clinical practice. A major challenge addresses difficult-to-treat areas, especially in the absence of significant body surface involvement. It is controversial whether the severity evaluation of patients with several affected areas (having at least one difficult-to-treat area) should be done differently from current methods. Scores used for special areas (PSSI, NAPSI and ESIF) allow an accurate assessment of disease severity in difficult-to-treat areas, but the issue of whether to integrate these scores into PASI, BSA or DLQI remains. The review’s purpose resides in providing an overview of the main current issues in determining psoriasis severity in patients with psoriasis in difficult-to-treat areas and suggesting possible solutions for the optimal integration of the area assessment in current scores: severity can be either established according to the highest calculated score (PASI or PSSI or NAPSI or ESIF) or by adding a correction factor in the calculation of PASI for special areas.
format Online
Article
Text
id pubmed-9785802
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97858022022-12-24 Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness Nicolescu, Alin Codrut Ionescu, Marius-Anton Constantin, Maria Magdalena Ancuta, Ioan Ionescu, Sinziana Niculet, Elena Tatu, Alin Laurentiu Zirpel, Henner Thaçi, Diamant Life (Basel) Review Psoriasis is not optimally controlled in spite of newly developed treatments, possibly due to the difficulty of objectively quantifying the disease’s severity, considering the limitations of the clinical scores used in clinical practice. A major challenge addresses difficult-to-treat areas, especially in the absence of significant body surface involvement. It is controversial whether the severity evaluation of patients with several affected areas (having at least one difficult-to-treat area) should be done differently from current methods. Scores used for special areas (PSSI, NAPSI and ESIF) allow an accurate assessment of disease severity in difficult-to-treat areas, but the issue of whether to integrate these scores into PASI, BSA or DLQI remains. The review’s purpose resides in providing an overview of the main current issues in determining psoriasis severity in patients with psoriasis in difficult-to-treat areas and suggesting possible solutions for the optimal integration of the area assessment in current scores: severity can be either established according to the highest calculated score (PASI or PSSI or NAPSI or ESIF) or by adding a correction factor in the calculation of PASI for special areas. MDPI 2022-12-07 /pmc/articles/PMC9785802/ /pubmed/36556415 http://dx.doi.org/10.3390/life12122050 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Nicolescu, Alin Codrut
Ionescu, Marius-Anton
Constantin, Maria Magdalena
Ancuta, Ioan
Ionescu, Sinziana
Niculet, Elena
Tatu, Alin Laurentiu
Zirpel, Henner
Thaçi, Diamant
Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness
title Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness
title_full Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness
title_fullStr Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness
title_full_unstemmed Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness
title_short Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness
title_sort psoriasis management challenges regarding difficult-to-treat areas: therapeutic decision and effectiveness
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785802/
https://www.ncbi.nlm.nih.gov/pubmed/36556415
http://dx.doi.org/10.3390/life12122050
work_keys_str_mv AT nicolescualincodrut psoriasismanagementchallengesregardingdifficulttotreatareastherapeuticdecisionandeffectiveness
AT ionescumariusanton psoriasismanagementchallengesregardingdifficulttotreatareastherapeuticdecisionandeffectiveness
AT constantinmariamagdalena psoriasismanagementchallengesregardingdifficulttotreatareastherapeuticdecisionandeffectiveness
AT ancutaioan psoriasismanagementchallengesregardingdifficulttotreatareastherapeuticdecisionandeffectiveness
AT ionescusinziana psoriasismanagementchallengesregardingdifficulttotreatareastherapeuticdecisionandeffectiveness
AT niculetelena psoriasismanagementchallengesregardingdifficulttotreatareastherapeuticdecisionandeffectiveness
AT tatualinlaurentiu psoriasismanagementchallengesregardingdifficulttotreatareastherapeuticdecisionandeffectiveness
AT zirpelhenner psoriasismanagementchallengesregardingdifficulttotreatareastherapeuticdecisionandeffectiveness
AT thacidiamant psoriasismanagementchallengesregardingdifficulttotreatareastherapeuticdecisionandeffectiveness